2nd Gene Therapy for Neurological Disorders Europe
Returning digitally in 2021, the 2nd Annual Gene Therapy for Neurological Disorders Europe meeting will possibly be your last chance to attend a European meeting without the airmiles!
Focusing on the industry’s challenges of developing and delivering gene therapies to the CNS and bringing fresh faces and emerging companies into the conversation, this is not one to miss as you seek to accelerate the development of your neurological gene therapy.
Discover the latest neurological targets, familiarise yourself with the European landscape, and debate and discuss with the leading minds of the field from the likes of UCB, Lysogene, UniQure and AskBio, as they seek to harness the opportunity and move from rare to common disorders such as Alzheimer’s, Parkinson’s and epilepsy.
Focusing on translation and ‘what’s new’ in the gene therapy for neurological disorders field, this year’s 3-day agenda has been developed alongside neurological experts from AskBio, Handl Therapeutics, Novartis and Spark Therapeutics to capture the most pressing challenges and new opportunities facing the field.
Discussing rare to common neurological disorders, attend the digital meeting in July to:
Hear the latest clinical updates from the most advanced companies to inform your future strategies
Discover the novel neurological targets being pursued by gene therapy developers to learn of the latest CNS opportunities
Discuss how to optimize the use of preclinical models and biomarkers for improved translation and reduced risk to patients
Ask the European Medicines Agency questions related to the specific regulatory challenges of designing trials for both rare and common disorders
Weigh up the advantages and disadvantages of established and novel routes of administration for CNS gene therapy delivery
Raise questions to the neurosurgeons at the forefront of neurosurgical delivery and hear their thoughts on the technical challenges facing different programs
Be a part of the debate and discussion related to measuring and overcoming CNS immunogenic responses
Don’t miss your opportunity to benchmark against your competitors, hear the state of the art technology advances and research in the field, and make new connections at the last digital European meeting, to revolutionise the development and delivery of your neurological gene therapy.